Citations

Clear

153 citation(s) found for "Thomas, Michael".

Aspiration Versus Stent‐Retriever as First‐Line Endovascular Therapy Technique for Primary Medium and Distal Intracranial Occlusions: A Propensity‐Score Matched Multicenter Analysis
Shaikh, Hamza , Khalife, Jane , Oak, Solomon , Abdalkader, Mohamad , Kass‐Hout, Tareq , Morsi, Rami Z. , Heit, Jeremy J. , Regenhardt, Robert W. , Diestro, Jose Danilo Bengzon , Ghozy, Sherief , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Puri, Ajit S , Dyzmann, Christian , Kan, Peter , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Capirossi, Carolina , Tjoumakaris, Stavropoula , Jabbour, Pascal , Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Chervak, Lina , Aziz, Yasmin , Bullrich, María Bres , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Patel, Aman B. , Lubicz, Boris , Guenego, Adrien , Dmytriw, Adam A , Liebeskind, David S. , Heit, Jeremy J , Ghozy, Sherief , Diestro, Jose Danilo B , Gonzalez, Nestor R , Aziz, Yasmin , Regenhardt, Robert W , Henninger, Nils , Alexandre, Andrea M , Morsi, Rami Z , Varela, Ricardo , Siegler, James E. , Zhang, Linda , Klein, Piers , Nguyen, Thanh N. , Cancelliere, Nicole M , Sweid, Ahmad , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Rouchaud, Aymeric , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Colasurdo, Marco , Marnat, Gaultier , Sibon, Igor , Das, Alvin S. , Ota, Takahiro , Yeo, Leonard Ll , Tan, Benjamin Yong‐Qiang , Martinez-Gutierrez, Juan Carlos , Salazar‐Marioni, Sergio , Sheth, Sunil A , Renieri, Leonardo , Mowla, Ashkan , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Jesser, Jessica , Schiphorst, Adrien ter , Yedavalli, Vivek , Harker, Pablo , Sposato, Luciano A. , Gory, Benjamin , Hecker, Constantin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Hsieh, Cheng‐Yang , Radu, Răzvan Alexandru , Fahed, Robert , Weyland, Charlotte S. , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | July 6, 2023 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/svin.123.000931 | PMID 41585056 Get It

Background For acute proximal intracranial artery occlusions, contact aspiration may be more effective than stent‐retriever for first‐line reperfusion therapy. Due to the lack of data regarding medium vessel occlusion thrombectomy, we evaluated outcomes according to first‐line technique in a large, multicenter registry. Methods Imaging, procedural, and clinical outcomes of patients with acute proximal medium vessel occlusions (M2, A1, or P1) or distal medium vessel occlusions (M3, A2, P2, or further) treated at 37 sites in 10 countries were analyzed according to first‐line endovascular technique (stent‐retriever versus aspiration). Multivariable logistic regression and propensity‐score matching were used to estimate the odds of the primary outcome, expanded Thrombolysis in Cerebral Infarction score of 2b–3 (“successful recanalization”), as well as secondary outcomes (first‐pass effect, expanded Thrombolysis in Cerebral Infarction 2c‐3, intracerebral hemorrhage, and 90‐day modified Rankin scale, 90‐day mortality) between treatment groups. Results Of the 440 included patients (44.5% stent‐retriever versus 55.5% aspiration), those treated with stent‐retriever had lower baseline Alberta Stroke Program Early Computed Tomography Scale scores (median 8 versus 9; P <0.01), higher National Institutes of Health Stroke Scale scores (median 13 versus 11; P =0.02), and nonsignificantly fewer medium‐distal occlusions (M3, A2, P2, or other: 17.4% versus 23.8%; P =0.10). Use of a stent‐retriever was associated with 15% lower odds of successful recanalization (odds ratio [OR], 0.85; [95% CI 0.74–0.98]; P =0.02), but this was not significant after multivariable adjustment in the total cohort (adjusted OR, 0.88; [95% CI 0.72–1.09]; P =0.24), or in the propensity‐score matched cohort (n=105 in each group) (adjusted OR, 0.94; [95% CI 0.75–1.18]; P =0.60). There was no significant association between technique and secondary outcomes in the propensity‐score matched adjusted models. Conclusion In this large, diverse, multinational medium vessel occlusion cohort, we found no significant difference in imaging or clinical outcomes with aspiration versus stent‐retriever thrombectomy.
Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2 (S47.006)
Marmura, Michael J. , Diener, Hans‐Christoph, Cowan, Robert P. , Starling, Amaal J. , Hirman, Joe, Brevig, Thomas, Cady, Roger, Marmura, Michael J , Cowan, Robert P

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202038 Get It

Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial
Starling, Amaal J. , Cowan, Robert P. , Buse, Dawn C. , Marmura, Michael J. , Hirman, Joe, Brevig, Thomas, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 12, 2023 | Volume: 63 | Issue: 2 | Pages: 264-274

10.1111/head.14434 | PMID 36633219 Get It

Abstract Objective To evaluate the effect of eptinezumab on patient‐reported outcomes in patients with chronic migraine (CM) and medication‐overuse headache (MOH). Background MOH is a secondary headache disorder commonly occurring in patients with CM and associated with functional and psychological impairments. Medication overuse and monthly headache and migraine days were reduced with eptinezumab compared with placebo as published previously; however, these outcomes do not fully capture the burden of migraine and treatment effect. Methods PROMISE‐2 was a phase 3, randomized, double‐blind, placebo‐controlled trial in adults with CM. Patients were randomized (1:1:1) to receive eptinezumab 100 mg, eptinezumab 300 mg, or placebo (up to 2 doses, 12 weeks apart). Patients completed the following patient‐reported outcomes: 6‐item Headache Impact Test (HIT‐6), Patient Global Impression of Change (PGIC), patient‐identified most bothersome symptom (PI‐MBS), and 36‐item Short‐Form Health Survey (SF‐36). Results A total of 431 CM patients (139, 147, and 145 patients in the eptinezumab 100 mg, eptinezumab 300 mg, and placebo groups, respectively) had MOH diagnosed at screening (40.2% of the total PROMISE‐2 population [ n = 1072]). In CM with MOH patients, both doses of eptinezumab were associated with clinically meaningful improvements in mean HIT‐6 total scores by week 4 and remained improved throughout the 24‐week study. Responder rates for individual HIT‐6 items were greater with eptinezumab than with placebo at all time points. At week 12, almost twice as many eptinezumab‐treated patients indicated the PGIC was “much” or “very much” improved (58.5% [79/135, 100 mg] and 67.4% [95/147, 300 mg] vs. 35.8% [48/134, placebo]). Patients in the eptinezumab groups showed numerically greater improvements over placebo in the PI‐MBS and SF‐36 scores. Conclusions This subgroup analysis in patients with CM/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient‐reported outcomes.
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study
Bassatne, Aya , Piggott, Thomas , Rahme, Maya , Fuleihan, Ghada El‐Hajj , Murad, Mohammad H, El-Hajj Fuleihan, Ghada , Piggott, Thomas , Murad, M. Hassan , Drake, Matthew T.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 563-584

10.1210/clinem/dgac630 | PMID 36545699 Get It

AbstractBackgroundIntegrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG implementation and treatment adherence. This applies to many debilitating diseases, including hypercalcemia of malignancy (HCM).ObjectiveEvaluate patient and physician values, preferences, and attitudes to better inform CPGs to treat HCM in adults.MethodsWe followed a mixed-methods approach. We conducted a systematic review using 5 databases to identify studies reporting on patient and physician values, costs and resources, feasibility, acceptability, and equity regarding HCM treatment. We also gathered data from different countries on the cost of multiple treatment modalities. We collected data on outcome prioritization from the CPG Working Group. Similarly, we collected data from patients with HCM regarding outcome prioritization and administered a questionnaire to evaluate their attitudes and perceptions toward treatment as well as treatment acceptability and feasibility.ResultsIn the systematic review, we included 2 cross-sectional surveys conducted on the same population of physicians who agreed that treating HCM alleviates symptoms and improves quality of life; however, harms and benefits should be thoroughly considered when deciding on the duration of treatment. We also included 2 studies on cost showing that intravenous (IV) bisphosphonate is more cost-effective than a combination of IV bisphosphonate and calcitonin and administration of IV zoledronic acid at home is more cost-effective than other IV bisphosphonates. The cost of zoledronic acid, denosumab, and cinacalcet varied widely among countries and types (brand vs generic). Both the CPG Working Group and patients with HCM agreed that the most important outcomes when deciding on treatment were survival and resolution of HCM, but there was some variability in the ratings for other outcomes.ConclusionUsing mixed methods, CPG developers can obtain meaningful information regarding evidence to decision criteria. In the case of HCM CPGs, this approach has provided the required contextual information and supported the development of evidence-based recommendations.
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
Fuleihan, Ghada El‐Hajj , Clines, Gregory A. , Hu, Mimi I. , Marcocci, Claudio , Murad, M. Hassan , Piggott, Thomas , Poznak, Catherine Van , Wu, Joy Y. , Drake, Matthew T. , El-Hajj Fuleihan, Ghada , Van Poznak, Catherine , Murad, M Hassan , Drake, Matthew T , Piggott, Thomas

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 507-528

10.1210/clinem/dgac621 | PMID 36545746 Get It

Abstract Background Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective chemotherapeutic drugs. Despite the widespread availability of efficacious medications to treat HCM, evidence-based recommendations to manage this debilitating condition are lacking. Objective To develop guidelines for the treatment of adults with HCM. Methods A multidisciplinary panel of clinical experts, together with experts in systematic literature review, identified and prioritized 8 clinical questions related to the treatment of HCM in adult patients. The systematic reviews (SRs) queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. An independent SR was conducted in parallel to assess patients' and physicians' values and preferences, costs, resources needed, acceptability, feasibility, equity, and other domains relevant to the Evidence-to-Decision framework as well as to enable judgements and recommendations. Results The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP). The following recommendations were based on low certainty of the evidence. The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory/recurrent HCM despite treatment with BP, the use of Dmab. The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM. The panel suggests (conditional recommendation) in adult patients with hypercalcemia due to parathyroid carcinoma, treatment with either a calcimimetic or an antiresorptive (IV BP or Dmab). The panel judges the treatments as probably accessible and feasible for most recommendations but noted variability in costs, resources required, and their impact on equity. Conclusions The panel's recommendations are based on currently available evidence considering the most important outcomes in HCM to patients and key stakeholders. Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence. The recommendations provide a framework for the medical management of adults with HCM and incorporate important decisional and contextual factors. The guidelines underscore current knowledge gaps that can be used to establish future research agendas.
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
Saporta, A. , Barry, John J., Omotola, Hope, O’Brien, Terence J. , Nadkarni, Siddhartha, Winawer, Melodie R., French, Jacqueline A. , Abou‐Khalil, Bassel , Alldredge, Brian K., Bebin, Martina , Cascino, Gregory D. , Cook, Mark , Detyniecki, Kamil , Dlugos, Dennis , Faught, Edward, Ficker, David M. , Fields, Madeline , Glynn, Simon, Halford, Jonathan J. , Haut, Sheryl R., Hegde, Manu , Kälviäinen, Reetta , Knowlton, Robert C. , Krishnamurthy, Kaarkuzhali Babu , Kwan, Patrick , Lowenstein, Daniel H. , Marcuse, Lara , Meador, Kimford J. , Mintzer, Scott , Pardoe, Heath , Penovich, Patricia , Singh, Rani K. , Szabó, C. Ákos , Szaflarski, Jerzy P. , Burneo, Jorge G. , Project, and the Human Epilepsy, French, Jacqueline A. , Kanner, Andres M, Saporta, Anita S, Kim, Dong H, Altalib, Hamada , Jetté, Nathalie , O'Brien, Terence J, Sperling, Michael, Abou-Khalil, Bassel, Alldredge, Brian, Cook, Mark J , Ficker, David, Gidal, Barry, Gelfand, Michael , Haut, Sheryl, Holmes, Manisha G, Kang, Joon, Klein, Pavel , Krishnamurthy, Kaarkuzhali, Kuzniecky, Ruben , Pardoe, Heath R , Park, Kristen , Szabo, Charles A, Lin Thio, K Liu, Halford, Jonathan J , French, Jacqueline , Meador, Kimford J , Burneo, Jorge G , Kanner, Andres Miguel , Kim, Dong , Sperling, Michael R. , Cole, Andrew J. , Devinsky, Orrin , Gidal, Barry E. , Holmes, Manisha , Kang, Joon Won , Somerville, Ernest , Thio, Liu Lin , Trinka, Eugen , Project, and the Human Epilepsy

Mayo Clinic

Neurology | December 20, 2022 | Volume: 100 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000201671 | PMID 36539302 Get It

Catastrophic acute failure of pelvic fixation in adult spinal deformity requiring revision surgery: a multicenter review of incidence, failure mechanisms, and risk factors
Martin, Christopher T. , Holton, Kenneth J. , Elder, Benjamin D. , Fogelson, Jeremy L. , Mikula, Anthony L. , Kleck, Christopher J. , Calabrese, David W., Ou-Yang, David , Lovecchio, Francis , Hu, Serena S. , Wood, Kirkham B. , Harper, R. A. Kemp , Ananthakrishnan, Dheera , Schell, Adam, Lieberman, Isador H. , Kisinde, Stanley , DeWald, Christopher J., Colman, Matthew W. , Phillips, Frank M. , Gelb, Daniel E. , Bruckner, Jacob J. , Ross, Lindsey , Johnson, J. Patrick , Kim, Terrence T. , Anand, Neel , Plummer, Zach, Park, Paul , Oppenlander, Mark E., Polly, David W. , Polly, David , Burger, Evalina L. , Patel, Vikas V. , Kim, Han Jo , Harper, Robert, Michael, Keith W. , Nolte, Michael Thomas , Cheng, Joseph S. , Plummer, Zachary J., Sembrano, Jonathan N. , Jones, Kristen E.

Mayo Clinic

Journal of Neurosurgery: Spine | September 23, 2022 | Volume: 38 | Issue: 1 | Pages: 98-106

10.3171/2022.6.spine211559 | PMID 36057123 Get It

OBJECTIVE There are few prior reports of acute pelvic instrumentation failure in spinal deformity surgery. The objective of this study was to determine if a previously identified mechanism and rate of pelvic fixation failure were present across multiple institutions, and to determine risk factors for these types of failures. METHODS Thirteen academic medical centers performed a retrospective review of 18 months of consecutive adult spinal fusions extending 3 or more levels, which included new pelvic screws at the time of surgery. Acute pelvic fixation failure was defined as occurring within 6 months of the index surgery and requiring surgical revision. RESULTS Failure occurred in 37 (5%) of 779 cases and consisted of either slippage of the rods or displacement of the set screws from the screw tulip head (17 cases), screw shaft fracture (9 cases), screw loosening (9 cases), and/or resultant kyphotic fracture of the sacrum (6 cases). Revision strategies involved new pelvic fixation and/or multiple rod constructs. Six patients (16%) who underwent revision with fewer than 4 rods to the pelvis sustained a second acute failure, but no secondary failures occurred when at least 4 rods were used. In the univariate analysis, the magnitude of surgical correction was higher in the failure cohort (higher preoperative T1-pelvic angle [T1PA], presence of a 3-column osteotomy; p < 0.05). Uncorrected postoperative deformity increased failure risk (pelvic incidence–lumbar lordosis mismatch > 10°, higher postoperative T1PA; p < 0.05). Use of pelvic screws less than 8.5 mm in diameter also increased the likelihood of failure (p < 0.05). In the multivariate analysis, a larger preoperative global deformity as measured by T1PA was associated with failure, male patients were more likely to experience failure than female patients, and there was a strong association with implant manufacturer (p < 0.05). Anterior column support with an L5–S1 interbody fusion was protective against failure (p < 0.05). CONCLUSIONS Acute catastrophic failures involved large-magnitude surgical corrections and likely resulted from high mechanical strain on the pelvic instrumentation. Patients with large corrections may benefit from anterior structural support placed at the most caudal motion segment and multiple rods connecting to more than 2 pelvic fixation points. If failure occurs, salvage with a minimum of 4 rods and 4 pelvic fixation points can be successful.
Temporal lobe interictal spikes disrupt encoding and retrieval of verbal memory: A subregion analysis
Camarillo‐Rodriguez, Liliana , Leenen, Iwin , Waldman, Zachary, Serruya, Mijail D. , Wanda, Paul A., Herweg, Nora A. , Kahana, Michael J. , Orosz, Iren, Podkorytova, Irina , Jobst, Barbara C. , Sheth, Sameer A. , Weiss, Shennan A. , Sperling, Michael R. , Podkorytova, Irina , Weiss, Shennan A , Sperling, Michael R , Jobst, Barbara , Rubinstein, Daniel , Lega, Bradley Charles , Gross, Robert E. , Worrell, Gregory A. , Davis, Kathryn A.

Mayo Clinic

Epilepsia | June 16, 2022 | Volume: 63 | Issue: 9 | Pages: 2325-2337

10.1111/epi.17334 | PMID 35708911 Get It

AbstractObjectiveThe medial temporal lobe (MTL) encodes and recalls memories and can be a predominant site for interictal spikes (IS) in patients with focal epilepsy. It is unclear whether memory deficits are due to IS in the MTL producing a transient decline. Here, we investigated whether IS in the MTL subregions and lateral temporal cortex impact episodic memory encoding and recall.MethodsSeventy‐eight participants undergoing presurgical evaluation for medically refractory focal epilepsy with depth electrodes placed in the temporal lobe participated in a verbal free recall task. IS were manually annotated during the pre‐encoding, encoding, and recall epochs. We examined the effect of IS on word recall using mixed‐effects logistic regression.ResultsIS in the left hippocampus (odds ratio [OR] = .73, 95% confidence interval [CI] = .63–.84, p < .001) and left middle temporal gyrus (OR = .46, 95% CI = .27–.78, p < .05) during word encoding decreased subsequent recall performance. Within the left hippocampus, this effect was specific for area CA1 (OR = .76, 95% CI = .66–.88, p < .01) and dentate gyrus (OR = .74, 95% CI = .62–.89, p < .05). IS in other MTL subregions or inferior and superior temporal gyrus and IS occurring during the prestimulus window did not affect word encoding (p > .05). IS during retrieval in right hippocampal (OR = .22, 95% CI = .08–.63, p = .01) and parahippocampal regions (OR = .24, 95% CI = .07–.8, p < .05) reduced the probability of recalling a word.SignificanceIS in medial and lateral temporal cortex contribute to transient memory decline during verbal episodic memory.
Practical considerations in epilepsy neurostimulation
Simpson, Hugh D. , Schulze‐Bonhage, Andreas , Cascino, Gregory D. , Fisher, Robert S. , Jobst, Barbara C. , Sperling, Michael R. , Lundstrom, Brian N. , Schulze-Bonhage, Andreas , Sperling, Michael R , Lundstrom, Brian Nils , Fisher, Robert , Jobst, Barbara

Mayo Clinic

Epilepsia | June 14, 2022 | Volume: 63 | Issue: 10 | Pages: 2445-2460

10.1111/epi.17329 | PMID 35700144 Get It

Abstract Neuromodulation is a key therapeutic tool for clinicians managing patients with drug‐resistant epilepsy. Multiple devices are available with long‐term follow‐up and real‐world experience. The aim of this review is to give a practical summary of available neuromodulation techniques to guide the selection of modalities, focusing on patient selection for devices, common approaches and techniques for initiation of programming, and outpatient management issues. Vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (DBS‐ANT), and responsive neurostimulation (RNS) are all supported by randomized controlled trials that show safety and a significant impact on seizure reduction, as well as a suggestion of reduction in the risk of sudden unexplained death in epilepsy (SUDEP). Significant seizure reductions are observed after 3 months for DBS, RNS, and VNS in randomized controlled trials, and efficacy appears to improve with time out to 7 to 10 years of follow‐up for all modalities, albeit in uncontrolled follow‐up or retrospective studies. A significant number of patients experience seizure‐free intervals of 6 months or more with all three modalities. Number and location of epileptogenic foci are important factors affecting efficacy, and together with comorbidities such as severe mood or sleep disorders, may influence the choice of modality. Programming has evolved—DBS is typically initiated at lower current/voltage than used in the pivotal trial, whereas target charge density is lower with RNS, however generalizable optimal parameters are yet to be defined. Noninvasive brain stimulation is an emerging stimulation modality, although it is currently not used widely. In summary, clinical practice has evolved from those established in pivotal trials. Guidance is now available for clinicians who wish to expand their approach, and choice of neuromodulation technique may be tailored to individual patients based on their epilepsy characteristics, risk tolerance, and preferences.